Core Insights - Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [3] - The company is advancing its lead candidate, verekitug, which targets the receptor for thymic stromal lymphopoietin (TSLP), into Phase 2 trials for chronic rhinosinusitis with nasal polyps, severe asthma, and chronic obstructive pulmonary disease [3] - The CEO, Rand Sutherland, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025 [1] Company Overview - Upstream Bio is dedicated to addressing unmet medical needs in patients underserved by current treatments [3] - Verekitug is the only known antagonist in clinical development targeting TSLP, a key cytokine in inflammatory responses [3] - The company aims to leverage verekitug's unique properties to improve patient outcomes in various immune-mediated diseases [3] Event Information - A live webcast of the CEO's fireside chat will be available on the company's website, with a replay posted afterward [2]
Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum